Sugi Predict

Sugi Predict / Compounds / SCHEMBL1492706

SCHEMBL1492706

SCHEMBL1492706

Cc1cc(-c2ccc(N)cc2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.61
▸ MAP4K4 O95819 3/20 0.56
▸ PIK3CB P42338 1/20 0.49
▸ UHRF1 Q96T88 1/20 0.46
▸ CCNC P24863 1/20 0.46
▸ CDK8 P49336 1/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ PSEN1 P49768 4/20 0.46
▸ PSEN2 P49810 4/20 0.46
▸ APH1B Q8WW43 4/20 0.46
▸ NCSTN Q92542 4/20 0.46
▸ APH1A Q96BI3 4/20 0.46
▸ PSENEN Q9NZ42 4/20 0.46
▸ WNT3A P56704 2/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ TLR9 Q9NR96 1/20 0.43
▸ TLR8 Q9NR97 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1896511 0.84 DYRK1A (0.65) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL30308690 0.84 DYRK1A (0.65) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL2684619 0.83 DYRK1A (0.52) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL6855459 0.83 DYRK1A (0.66) DYRK1AMAP4K4UHRF1CCNCCDK8
Iodide SCHEMBL9618570 0.82 DYRK1A (0.63) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL15333232 0.82 PIK3CB (0.56) MAP4K4PIK3CB
SCHEMBL11229734 0.82 TDP1 (0.56) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL14680822 0.81 DYRK1A (0.63) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL1159709 0.81 DYRK1A (0.56) DYRK1AMAP4K4PIK3CBUHRF1CCNC
SCHEMBL17432853 0.81 MAP4K4 (0.43) DYRK1AMAP4K4PIK3CBUHRF1CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192613-A1 Charged Ion Channel Blockers and Methods for Use NOCION THERAPEUTICS INC (US) 2023-06-22 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
EP-2958919-B1 DIHYDROPTERIDINONES I BOEHRINGER INGELHEIM INT (DE) 2019-05-22 — — EP disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9771378-B2 Fused morpholinopyrimidines and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
US-9771378-B2 Fused morpholinopyrimidines and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
US-9771378-B2 Fused morpholinopyrimidines and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
WO-2009137404-A1 UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-11-12 — — WO disclosed
WO-2009137404-A1 UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-11-12 — — WO disclosed
US-20090215759-A1 MODULATORS FOR AMYLOID BETA HOFFMANN-LA ROCHE, INC. 2009-08-27 — — US disclosed
WO-2009103652-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-08-27 — — WO disclosed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 — — WO disclosed
EP-0975593-A1 INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2000-02-02 — — EP disclosed
WO-1998050358-A1 INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1998-11-12 — — WO disclosed
US-4376775-A N-[4-(4-Pyridinyl)phenyl]ureas and their cardiotonic use STERLING DRUG INC. (US) 1983-03-15 — — US disclosed
US-4366319-A Process for preparing 5-(pyridinyl)benzoxazol-2(3H)-ones STERLING DRUG INC. (US) 1982-12-28 — — US disclosed
US-4310531-A 5-(Pyridinyl)-benzoxazol-2(3H)-ones and their use as cardiotonics STERLING DRUG INC. (US) 1982-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK DYRK1A 142/4885MAP4K4 186/4885PIK3CB 1106/4885
US-20230192613-A1 Charged Ion Channel Blockers and Methods for Use TRPV1, TRPV2, TRPV5 DYRK1A 4362/4885MAP4K4 2360/4885PIK3CB 1437/4885
US-20090215759-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, APOB DYRK1A 3762/4885MAP4K4 4592/4885PIK3CB 2015/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK DYRK1A 136/4885MAP4K4 169/4885PIK3CB 912/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK DYRK1A 136/4885MAP4K4 169/4885PIK3CB 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.